Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INCA035784 in Participants With Myeloproliferative Neoplasms
NCT07008118Phase 1Recruiting
- Sponsor
- Incyte
- Start
- Oct 2025
- Primary completion
- Mar 2028
- Modality
- Antibody Conjugates, Bispecific Antibodies, T-cell Engagers
- Countries
- 5
01
Overview
Phase 1, open-label trial of INCA035784 in Myeloproliferative Neoplasm (MPN) (2 arms), sponsored by Incyte. Primary endpoints: Dose Limiting Toxicities at 28 days, Treatment-emergent Adverse Events and 1 more. Started Oct 2025; status: recruiting.
02
Drugs
INCA035784
03
Conditions
Myeloproliferative Neoplasm (MPN)
Beyond the preview
Go deeper on NCT07008118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07008118.